

Anne Nguyen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/746535/publications.pdf>

Version: 2024-02-01

14
papers

2,141
citations

932766

10
h-index

1058022

14
g-index

14
all docs

14
docs citations

14
times ranked

1649
citing authors

#	ARTICLE	IF	CITATIONS
1	CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2005, 97, 30-39.	3.0	867
2	The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2007, 101, 113-121.	1.1	520
3	Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 61-74.	2.3	424
4	Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 450-458.	1.0	102
5	Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 907-914.	1.1	62
6	Estrogen Receptor Genotypes Influence Hot Flash Prevalence and Composite Score Before and After Tamoxifen Therapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 5849-5854.	0.8	49
7	Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 643-650.	1.1	37
8	Comparison of subjective and objective hot flash measures over time among breast cancer survivors initiating aromatase inhibitor therapy. <i>Menopause</i> , 2009, 16, 653-659.	0.8	24
9	A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 121-129.	1.1	17
10	Sequence diversity and functional characterization of the 5'??-regulatory region of human CYP2C19. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 199-206.	5.7	14
11	Antiestrogen pathway (aromatase inhibitor). <i>Pharmacogenetics and Genomics</i> , 2009, 19, 554-555.	0.7	10
12	Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 617-624.	1.1	7
13	A Mixture Model Approach in Gene-Environment Interactions for Binary Phenotypes. <i>Journal of Biopharmaceutical Statistics</i> , 2008, 18, 1150-1177.	0.4	6
14	Estimating a Positive False Discovery Rate for Variable Selection in Pharmacogenetic Studies. <i>Journal of Biopharmaceutical Statistics</i> , 2007, 17, 883-902.	0.4	2